Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Vial"

213 News Found

Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes
News | March 24, 2025

Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes

Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)


BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon in UK
Drug Approval | March 21, 2025

BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon in UK

PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions


Biocon Biologics and Civica collaborate to expand Insulin Aspart access in US
News | March 07, 2025

Biocon Biologics and Civica collaborate to expand Insulin Aspart access in US

There are 38.4 million people with diabetes in the United States


Glenmark Pharmaceuticals acquires and launches acetylcysteine injection
News | March 03, 2025

Glenmark Pharmaceuticals acquires and launches acetylcysteine injection

Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA


Borosil Scientific to shift unit at Ambad to Bharuch
News | February 27, 2025

Borosil Scientific to shift unit at Ambad to Bharuch

This will lead to the consolidation and optimization of the company's operations related to the manufacturing of ampoules and vials


Glenmark Pharmaceuticals USA launches Epinephrine Injection USP
News | February 27, 2025

Glenmark Pharmaceuticals USA launches Epinephrine Injection USP

This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.


Biocon Biologics launches Yesintek Biosimilar to Stelara in US
News | February 25, 2025

Biocon Biologics launches Yesintek Biosimilar to Stelara in US

YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis


Briefs: Caplin Point Laboratories, Hikal and Cipla
Drug Approval | February 10, 2025

Briefs: Caplin Point Laboratories, Hikal and Cipla

Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru


Piramal Critical Care announces US launch of Chlorpromazine Hydrochloride for Injection
News | January 23, 2025

Piramal Critical Care announces US launch of Chlorpromazine Hydrochloride for Injection

The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care


Akums commissions new manufacturing facility for Lyophilized and Sterile dosage
News | January 02, 2025

Akums commissions new manufacturing facility for Lyophilized and Sterile dosage

The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products